Paclitaxel has been widely used in chemotherapy of gynecological malignant tumors. Hypersensitivity reactions to paclitaxel are common complications during its treatment, which can endanger the life of patients in severe cases. Therefore, prevention of paclitaxel-induced hypersensitivity reactions, timely diagnosis and standardized treatments are important to improve the overall efficacy of paclitaxel antitumor therapy and to reduce the risk of mortality. This consensus has formulated the grading, diagnosis, treatment, and prevention of hypersensitivity reactions to paclitaxel chemotherapy, in order to provide reference for the standardized prevention and diagnosis and treatment of hypersensitivity reactions caused by paclitaxel chemotherapy for gynecological malignant tumors.